Lv6
1790 积分 2023-11-28 加入
Structure-based classification predicts drug response in EGFR-mutant NSCLC
4天前
已完结
First-Line Osimertinib for Previously Untreated Patients With NSCLC and Uncommon EGFR Mutations
18天前
已完结
Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer. Herceptin Multinational Investigator Study Group
1个月前
已关闭
Phase I and II clinical trials of trastuzumab
1个月前
已完结
Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease
1个月前
已完结
Population pharmacokinetics of trastuzumab in patients With HER2+ metastatic breast cancer
1个月前
已完结
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma
1个月前
已关闭
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma
1个月前
已关闭
Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial
1个月前
已完结
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
1个月前
已完结
皖公网安备34019202002308
